

Neil E Kay

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5244265/neil-e-kay-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

356
papers

11,680
citations

57
h-index

104
g-index

369
ext. papers

13,309
ext. citations

4
avg, IF

5.76
L-index

#	Paper	IF	Citations
356	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022 , 12, 18	7	1
355	CLL update 2022: A continuing evolution in care.. <i>Blood Reviews</i> , 2022 , 100930	11.1	1
354	Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.. <i>Blood</i> , 2022 ,	2.2	4
353	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. <i>Blood</i> , 2021 , 138, 906-906	2.2	0
352	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021 , 138, 2777-2777	2.2	
351	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. <i>Hematological Oncology</i> , 2021 ,	1.3	0
350	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2021 , 97, 90	7.1	4
349	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021 , 149, 535-545	7.5	0
348	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 47	7	1
347	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021 , 29, 1529-1540	11.7	12
346	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021 , 138, 149-159	2.2	4
345	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021 , 137, 2046-2056	2.2	4
344	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. <i>Scientific Reports</i> , 2021 , 11, 8318	4.9	2
343	The prognostic significance of del6q23 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E203-E206	7.1	1
342	SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. <i>Blood Cancer Journal</i> , 2021 , 11, 93	7	1
341	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021 , 11, 86	7	4
340	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3441-3452	2.2	65

339	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). <i>Leukemia</i> , 2021 , 35, 239-244	10.7	7
338	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021 , 100, 143-155	3	7
337	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021 , 137, 216-231	2.2	17
336	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021 , 2, 54-69	7	6
335	Chronic lymphocytic leukemia B-cell-derived TNF α impairs bone marrow myelopoiesis. <i>iScience</i> , 2021 , 24, 101994	6.1	3
334	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 17	22.4	4
333	The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). <i>Vaccine</i> , 2021 , 39, 1122-1130	4.1	13
332	Upregulation of AXL and Eatenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. <i>Blood Cancer Journal</i> , 2021 , 11, 37	7	
331	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021 , 9, 1035-1046	12.5	2
330	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2021 ,	10.7	1
329	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021 , 11, 140	7	0
328	Early intervention in asymptomatic chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2021 , 19, 92-103	0.6	3
327	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. <i>Leukemia</i> , 2020 , 34, 1979-1983	10.7	1
326	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020 , 9, 3390-3399	4.8	19
325	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020 , 95, 906-917	7.1	6
324	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Advances</i> , 2020 , 4, 1407-1418	7.8	3
323	Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation. <i>Blood</i> , 2020 , 136, 42-43	2.2	
322	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020 , 136, 35-36	2.2	

321	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020 , 136, 26-27	2.2	
320	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 10-12	2.2	
319	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020 , 136, 28-29	2.2	
318	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020 , 136, 47-48	2.2	3
317	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
316	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020 , 136, 3-4	2.2	
315	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2	
314	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 1-1	2.2	
313	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
312	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 16-17	2.2	1
311	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
310	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 50-51	2.2	
309	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 39-40	2.2	1
308	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020 , 105, 2675-2678	6.6	11
307	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2383-2388	1.9	11
306	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020 , 95, E57-E60	7.1	5
305	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020 , 25, 974-980	5.7	5
304	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020 , 97, 106432	2.7	16

303	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1581-1589	4.5	2
302	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. <i>Human Molecular Genetics</i> , 2020 , 29, 2761-2774	5.6	4
301	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect CLL Registry. <i>EJHaem</i> , 2020 , 1, 188-198	0.9	1
300	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020 , 105, 765-773	6.6	31
299	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 1613-1620	6.6	6
298	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2712-2719	1.9	28
297	Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. <i>Oncotarget</i> , 2019 , 10, 60-75	3.3	5
296	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019 , 33, 2111-2115	10.7	10
295	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019 , 9, 59	7	2
294	Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). <i>Acta Haematologica</i> , 2019 , 142, 224-232	2.7	0
293	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 134, 688-698	2.2	16
292	Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019 , 381, 432-443	59.2	322
291	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 865-865	2.2	9
290	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. <i>Blood</i> , 2019 , 134, 53-53	2.2	1
289	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019 , 134, 4306-4306	2.2	3
288	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 679-679	2.2	1
287	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019 , 134, 3050-3050	2.2	2
286	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019 , 134, 33-33	2.2	22

285	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carcs. <i>Blood</i> , 2019 , 134, 3868-3868	2.2	5
284	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. <i>Blood</i> , 2019 , 134, 2859-2859	2.2	4
283	Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7525-7525	2.2	1
282	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. <i>Blood</i> , 2019 , 134, 3022-3022	2.2	
281	A Role for TNF- β in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. <i>Blood</i> , 2019 , 134, 4276-4276	2.2	
280	ECatenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance. <i>Blood</i> , 2019 , 134, 1739-1739	2.2	
279	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019 , 134, 852-852	2.2	
278	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019 , 134, 3037-3037	2.2	
277	B-cell prolymphocytic leukemia has 3 subsets. <i>Blood</i> , 2019 , 134, 1777-1778	2.2	1
276	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019 , 94, 338-345	7.1	11
275	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. <i>Blood</i> , 2019 , 133, 697-709	2.2	253
274	Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2019 , 33, 638-652	10.7	15
273	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018 , 103, e237-e240	6.6	9
272	Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018 , 11, 337-349	2.8	9
271	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018 , 131, 2541-2551	2.2	15
270	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect CLL cohort study. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2327-2335	1.9	3
269	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 114-124.e2	2	16
268	Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. <i>Blood</i> , 2018 , 131, 365-368	2.2	11

267	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018 , 101, 703	3.8	5
266	Analytical Considerations in Nanoscale Flow Cytometry of Extracellular Vesicles to Achieve Data Linearity. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1612-1624	7	26
265	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018 , 183, 421-427	4.5	25
264	A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). <i>Blood</i> , 2018 , 132, LBA-4-LBA-4	2.2	40
263	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. <i>Blood</i> , 2018 , 132, 961-961	2.2	3
262	Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>Blood</i> , 2018 , 132, 728-728	2.2	1
261	Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial. <i>Blood</i> , 2018 , 132, 236-236	2.2	6
260	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. <i>Blood</i> , 2018 , 132, 1833-1833	2.2	
259	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018 , 132, 3116-3116	2.2	
258	Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions. <i>Blood</i> , 2018 , 132, 1865-1865	2.2	
257	Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance. <i>Blood</i> , 2018 , 132, 3125-3125	2.2	
256	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018 , 132, 1857-1857	2.2	
255	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018 , 132, 586-586	2.2	1
254	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018 , 132, 4414-4414	2.2	1
253	Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment. <i>Blood</i> , 2018 , 132, 3132-3132	2.2	
252	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018 , 132, 4399-4399	2.2	
251	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. <i>Blood</i> , 2018 , 132, 4394-4394	2.2	
250	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). <i>Blood</i> , 2018 , 132, 5538-5538	2.2	

249	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017 , 129, 3419-3427	2.2	244
248	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017 , 92, E164-E166	7.1	2
247	Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. <i>American Journal of Hematology</i> , 2017 , 92, 759-763	7.1	16
246	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e22-e25	6.6	8
245	CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017 , 178, 99-105	4.5	15
244	Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017 , 178, 394-402	4.5	37
243	How I treat autoimmune hemolytic anemia. <i>Blood</i> , 2017 , 129, 2971-2979	2.2	100
242	Reply to S. Opat et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4094-4095	2.2	1
241	Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2989-2992	2.2	10
240	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017 , 92, 1362-1369	7.1	8
239	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1376-1383	1.9	30
238	SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells. <i>British Journal of Haematology</i> , 2017 , 178, 155-158	4.5	10
237	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1630-1639	1.9	71
236	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2017 , 1, 2433-2443	7.8	7
235	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017 , 130, 831-831 ²	2.2	3
234	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. <i>Blood</i> , 2017 , 130, 927-927	2.2	
233	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <i>Lancet Haematology</i> , 2016 , 3, e407-14	14.6	15
232	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , 2016 , 175, 892-903	4.5	37

231	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016 , 7, 10933	17.4	70
230	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 677-80	7.1	9
229	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016 , 128, 2041-2041	2.2	3
228	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. <i>Blood</i> , 2016 , 128, 2451-2451	2.2	1
227	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. <i>Blood</i> , 2016 , 128, 4364-4364	2.2	1
226	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016 , 128, 4392-4392	2.2	7
225	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. <i>Blood</i> , 2016 , 128, 4772-4772	2.2	4
224	Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 968-968	2.2	3
223	A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016 , 7, 78269-78280	3.3	7
222	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. <i>Blood</i> , 2016 , 128, 2020-2020	2.2	
221	Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group. <i>Blood</i> , 2016 , 128, 4373-4373	2.2	
220	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. <i>Blood</i> , 2016 , 128, 5585-5585	2.2	
219	The Role of Splenectomy in the Care and Treatment of the CLL Patient. <i>Blood</i> , 2016 , 128, 5575-5575	2.2	
218	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect CLL Registry. <i>Blood</i> , 2016 , 128, 5941-5941	2.2	
217	Epigenetic Silencing of Catalase Induces Accumulation of Reactive Oxygen Species in Chronic Lymphocytic Leukemia B Cells Leading to Activation of Axl: An Escape Strategy?. <i>Blood</i> , 2016 , 128, 4363-4363	2.2	23
216	Bone Marrow (BM) Hematopoietic Dysfunction in Chronic Lymphocytic Leukemia (CLL) - Association with Leukemic Burden and Reversibility with Therapeutic Responses.. <i>Blood</i> , 2016 , 128, 2013-2013	2.2	
215	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. <i>Blood</i> , 2016 , 128, 3228-3228	2.2	
214	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016 , 128, 5592-5592	2.2	1

213	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. <i>American Journal of Hematology</i> , 2016 , 91, 687-91	7.1	11
212	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.2	75
211	Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2409-16	1.9	12
210	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016 , 91, 1090-1095	7.1	43
209	Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. <i>Journal of Oncology Practice</i> , 2015 , 11, 252-8	3.1	77
208	Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015 , 169, 445-8	4.5	31
207	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. <i>EBioMedicine</i> , 2015 , 2, 572-82	8.8	34
206	Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2303-12	6.1	25
205	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <i>Haematologica</i> , 2015 , 100, 1180-8	6.6	53
204	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 492-8	2.2	44
203	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015 , 125, 1676-8	2.2	57
202	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015 , 121, 2883-91	6.4	47
201	Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 334-8	7.1	56
200	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. <i>Clinical Cancer Research</i> , 2015 , 21, 2115-26 ⁹	12.9	51
199	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 1713-1713	2.2	1
198	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. <i>Blood</i> , 2015 , 126, 2935-2935	2.2	15
197	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 2950-2950	2.2	5
196	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. <i>Blood</i> , 2015 , 126, 4169-4169	2.2	3

195	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. <i>Blood</i> , 2015 , 126, 5265-5265 ^{2,3} 4		
194	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. <i>Blood</i> , 2015 , 126, 717-717	2.2	7
193	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015 , 126, 834-834	2.2	15
192	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2926-2926	2.2	
191	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL Cohort Study. <i>Blood</i> , 2015 , 126, 3284-3284	2.2	
190	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2015 , 126, 2930-2930	2.2	
189	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL Registry. <i>Blood</i> , 2015 , 126, 4483-4483	2.2	
188	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. <i>Blood</i> , 2015 , 126, 5264-5264	2.2	
187	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL Registry. <i>Blood</i> , 2015 , 126, 5270-5270	2.2	
186	How we treat Richter syndrome. <i>Blood</i> , 2014 , 123, 1647-57	2.2	116
185	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 49-62	2.2	202
184	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 213-23	59.2	1154
183	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014 , 120, 2000-5	6.4	27
182	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 42-8	2.2	50
181	A novel method for analysis of human T cell repertoires by real-time PCR. <i>Journal of Immunological Methods</i> , 2014 , 412, 24-34	2.5	1
180	Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. <i>British Journal of Haematology</i> , 2014 , 164, 146-50	4.5	17
179	The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2778-84	1.9	23
178	Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012. <i>Leukemia Research</i> , 2014 , 38, 299-303	2.7	30

177	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014 , 207, 19-30	2.3	5
176	Critical signal transduction pathways in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 792, 215-39	3.6	7
175	CGH protocols: chronic lymphocytic leukemia. <i>Methods in Molecular Biology</i> , 2013 , 973, 87-98	1.4	2
174	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013 , 45, 868-76	36.3	147
173	Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Leukemia and Lymphoma</i> , 2013 , 54, 476-82	1.9	10
172	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013 , 162, 774-82	4.5	151
171	Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). <i>Cancer</i> , 2013 , 119, 3788-96	6.4	40
170	Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2013 , 121, 4137-41	2.2	72
169	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 122, 1891-9	2.2	157
168	The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. <i>PLoS ONE</i> , 2013 , 8, e83830	3.7	67
167	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. <i>Blood</i> , 2013 , 122, 1642-1642	2.2	5
166	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. <i>Blood</i> , 2013 , 122, 4178-4178	2.2	2
165	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013 , 122, 4179-4179	2.2	4
164	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 2855-2855	2.2	
163	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. <i>Blood</i> , 2013 , 122, 3375-3375	2.2	
162	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance). <i>Blood</i> , 2013 , 122, 2882-2882	2.2	
161	Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 720-9	0.6	9
160	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 843-6	2.2	63

159	Predicting clinical outcome in B-chronic lymphocytic leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012</i> , 394-8	7.1	1
158	Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). <i>Cancer, 2012</i> , 118, 1827-37	6.4	30
157	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology, 2012</i> , 30, 2483-91	2.2	100
156	Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production. <i>Blood, 2012</i> , 120, 3928-3928	2.2	
155	Very High Risk CLL Characterized by a Double Hit Clone with Both 11q22 and 17p13 Deletion.. <i>Blood, 2012</i> , 120, 2486-2486	2.2	
154	The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.. <i>Blood, 2012</i> , 120, 2877-2877	2.2	
153	Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy. <i>Blood, 2012</i> , 120, 3927-3927	2.2	
152	Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.. <i>Blood, 2012</i> , 120, 2893-2893	2.2	
151	Clonal Chromosomal Anomalies Similar to CLL and Other Hematologic Malignancies Can Be Found in Normal Individuals. <i>Blood, 2012</i> , 120, 873-873	2.2	
150	Extramedullary Chronic Lymphocytic Leukemia: Systematic Analysis of Cases Reported Between 1975 and 2010. <i>Blood, 2012</i> , 120, 4607-4607	2.2	
149	Chronic Lymphocytic Leukemia in Young (≤ 55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.. <i>Blood, 2012</i> , 120, 2901-2901	2.2	
148	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood, 2012</i> , 120, 3865-3865	2.2	
147	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's Syndrome): Large Retrospective Analysis From a Single Institution.. <i>Blood, 2012</i> , 120, 2902-2902	2.2	
146	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood, 2012</i> , 120, 4252-4252	2.2	
145	The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. <i>Blood, 2011</i> , 117, 1928-37	2.2	97
144	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood, 2011</i> , 117, 1911-6	2.2	102
143	Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin $\alpha 4 \beta 1$ (VLA-4) with natalizumab can overcome this resistance. <i>British Journal of Haematology, 2011</i> , 155, 53-64	4.5	80
142	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. <i>Leukemia and Lymphoma, 2011</i> , 52, 374-86	1.9	1

141	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. <i>Clinical Medicine Insights: Oncology</i> , 2011 , 5, 45-53	1.8	7
140	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1425-34	1.9	11
139	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). <i>Blood</i> , 2011 , 118, 1790-1790	2.2	1
138	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011 , 118, 2836-2836	2.2	1
137	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011 , 118, 288-288	2.2	3
136	Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,. <i>Blood</i> , 2011 , 118, 3899-3899	2.2	2
135	Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011 , 118, 799-799	2.2	1
134	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011 , 2, 95-113	0.9	35
133	Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse. <i>Blood</i> , 2011 , 118, 2838-2838	2.2	
132	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. <i>Blood</i> , 2011 , 118, 3903-3903	2.2	
131	Global Genomic Status At Diagnosis Informs Clinical Outcome in B-Chronic Lymphocytic Leukemia: Stable Versus Progressive Disease. <i>Blood</i> , 2011 , 118, 1772-1772	2.2	
130	Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,. <i>Blood</i> , 2011 , 118, 3898-3898	2.2	
129	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. <i>Blood</i> , 2011 , 118, 3881-3881	2.2	
128	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. <i>Blood</i> , 2011 , 118, 4152-4152	2.2	
127	TRIS (DIBENZYLIDENEACETONE) Dipalladium a Small-Molecule Palladium Complex Is Effective in the Induction of Apoptosis for B-Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2011 , 118, 2851-2851	2.2	
126	Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,. <i>Blood</i> , 2011 , 118, 3882-3882	2.2	
125	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 2085-2085	2.2	
124	Mesenchymal Stromal Cells Derived From Chronic Lymphocytic Leukemic Patients Express Different Genes and Produce Different Cytokines Compared to MSC Derived From Normal Subjects,. <i>Blood</i> , 2011 , 118, 3872-3872	2.2	

123	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Blood</i> , 2011 , 118, 4610-4610	2.2	
122	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. <i>Blood</i> , 2011 , 118, 3538-3538	2.2	
121	Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. <i>British Journal of Haematology</i> , 2010 , 151, 152-8	4.5	50
120	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 203, 161-8		33
119	Autoimmune complications in chronic lymphocytic leukaemia (CLL). <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 47-59	4.2	69
118	Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010 , 51, 620-7	1.9	47
117	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. <i>Blood</i> , 2010 , 115, 1755-64	2.2	181
116	LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. <i>Blood</i> , 2010 , 116, 2975-83	2.2	115
115	Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. <i>Blood</i> , 2010 , 116, 2984-93	2.2	98
114	Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2010 , 116, 2180-7	6.4	29
113	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010 , 116, 4777-87	6.4	91
112	Circulating endothelial cells in chronic lymphocytic leukemia: more evidence of disturbed angiogenesis. <i>Leukemia and Lymphoma</i> , 2009 , 50, 8-9	1.9	2
111	N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 588-92	1.9	12
110	Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3959-63	2.2	109
109	Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. <i>Clinical Cancer Research</i> , 2009 , 15, 1250-8	12.9	102
108	Reply to R.S. Go. <i>Journal of Clinical Oncology</i> , 2009 , 27, e45-e45	2.2	1
107	Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. <i>Epigenomics</i> , 2009 , 1, 39-61	4.4	49
106	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2009 , 115, 363-72	6.4	64

105	Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009 , 146, 660-4	4.5	13
104	Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. <i>British Journal of Haematology</i> , 2009 , 147, 471-83	4.5	65
103	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1261-8	1.9	60
102	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. <i>Blood</i> , 2009 , 114, 4441-50	2.2	260
101	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. <i>Blood</i> , 2009 , 113, 535-7	2.2	57
100	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009 , 113, 4188-96	2.2	91
99	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. <i>Blood</i> , 2009 , 113, 5568-74	2.2	112
98	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. <i>Blood</i> , 2009 , 114, 957-64	2.2	134
97	Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome.. <i>Blood</i> , 2009 , 114, 1265-1265	2.2	
96	Aberrant Regulation of the LEF-1 Locus in Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL): A Possible Role for Epigenetic Regulation.. <i>Blood</i> , 2009 , 114, 669-669	2.2	
95	Complex Interstitial Deletions of 11q and Copy-Neutral Loss of Heterozygosity of 11q Are Detected by Whole Genome Copy Number Variation Analysis of Early-Intermediate Stage, High Risk Chronic Lymphocytic Leukemia Patients.. <i>Blood</i> , 2009 , 114, 1245-1245	2.2	
94	CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. <i>British Journal of Haematology</i> , 2008 , 140, 537-46	4.5	131
93	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2008 , 141, 615-21	4.5	84
92	Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. <i>Diagnostic Pathology</i> , 2008 , 3, 16	3	32
91	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 49-56	1.9	146
90	Usefulness of Risk Stratification in the Treatment of Patients with Chronic Lymphocytic Leukemia. <i>Clinical Leukemia</i> , 2008 , 2, 46-54		
89	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1923-30	2.2	254
88	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Cancer</i> , 2008 , 113, 2110-8	6.4	62

87	Controversies in the front-line management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2008 , 32, 679-88	2.7	8
86	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. <i>Blood</i> , 2008 , 112, 2065-2065	2.2	1
85	Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. <i>Blood</i> , 2008 , 112, 3125-3125	2.2	2
84	Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL. <i>Blood</i> , 2008 , 112, 3144-3144	2.2	2
83	Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy. <i>Blood</i> , 2008 , 112, 43-43	2.2	5
82	Platelet-Derived Growth Factor (PDGF) Secreted by Chronic Lymphocytic Leukemic B-Cells Is Capable of Regulating the Activation and Function of Mesenchymal Stem Cells: Implications for Leukemic Cell/Stromal Cell Crosstalk. <i>Blood</i> , 2008 , 112, 355-355	2.2	
81	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. <i>Blood</i> , 2008 , 112, 3124-3124	2.2	1
80	De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson/Mayo Clinic Experience.. <i>Blood</i> , 2008 , 112, 1056-1056	2.2	1
79	Overexpression of the LEF-1 and TCF4 Transcription Factors in B-CLL: Further Evidence for a Role of the Wnt Signaling Pathway in B-CLL Biology and Leukemogenesis. <i>Blood</i> , 2008 , 112, 544-544	2.2	1
78	Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.. <i>Blood</i> , 2008 , 112, 1067-1067	2.2	
77	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. <i>Blood</i> , 2008 , 112, 3771-3771	2.2	
76	Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2412-7	1.9	82
75	Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2007 , 109, 2291-8	6.4	131
74	Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". <i>Leukemia Research</i> , 2007 , 31, 899-906	2.7	57
73	Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007 , 31, 1737-40	2.7	13
72	Prognostic factors in chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 49-55	4.4	10
71	Chronic lymphocytic leukemia: biology and current treatment. <i>Current Oncology Reports</i> , 2007 , 9, 345-526.	3.3	8
70	Community-based phase II trial of PCR for CLL/SLL patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007 , 22, 713-4; author reply 715-7	3.9	4

69	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 405-11	2.2	258
68	Combination therapies for previously untreated CLL. <i>Lancet, The</i> , 2007 , 370, 197-198	4.0	3
67	Comprehensive management of the CLL patient: a holistic approach. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 324-31	3.1	12
66	Comprehensive Management of the CLL Patient: A Holistic Approach. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 324-331	3.1	1
65	Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007 , 110, 2050-2050	2.2	1
64	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. <i>Blood</i> , 2007 , 110, 337-337	2.2	
63	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. <i>Blood</i> , 2007 , 110, 746-746	2.2	
62	Dietary Products Induce Apoptosis in CLL B Cells and Reveal Potential as a Therapeutic Combination That Can Overcome Stromal Cell Mediated Protection.. <i>Blood</i> , 2007 , 110, 3130-3130	2.2	
61	Characterization of Microvesicles in B-Cell Chronic Lymphocytic Leukemia (CLL): A Potential Mediator in CLL B Cell Disease Progression?.. <i>Blood</i> , 2007 , 110, 747-747	2.2	
60	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. <i>Blood</i> , 2007 , 110, 2615-2615	2.2	
59	Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 167, 177-81		31
58	The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2006 , 33, 174-85	5.5	42
57	T-cell abnormalities in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1197-8	1.9	4
56	Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4634-41	2.2	208
55	Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia. <i>Seminars in Hematology</i> , 2006 , 43, S50-4	4	13
54	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.. <i>Blood</i> , 2006 , 108, 234-234	2.2	1
53	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. <i>Blood</i> , 2006 , 108, 2785-2785	2.2	1
52	Alemtuzumab and Rituximab for Therapy of Patients with Early Stage High Risk CLL: Report of a Planned Interim Analysis.. <i>Blood</i> , 2006 , 108, 2829-2829	2.2	4

51	The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial.. <i>Blood</i> , 2006 , 108, 36-36	2.2	2
50	Elevated HIF-1 β levels in CLL B Cells May Explain Their Autocrine VEGF Secretion.. <i>Blood</i> , 2006 , 108, 583-583	2.2	
49	Inhibition of GSK-3 Induces Apoptosis of CLL Cells by Abrogating NF κ B Nuclear Activity.. <i>Blood</i> , 2006 , 108, 2797-2797	2.2	
48	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006 , 108, 817-817	2.2	
47	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. <i>Blood</i> , 2006 , 108, 586-586	2.2	
46	Expression and Functional Analysis of Activation-Induced Deaminase (AID) in Normal Human B Lymphocytes.. <i>Blood</i> , 2006 , 108, 934-934	2.2	
45	D Gene Usage Predicts Clinical Outcome in Patients with Low Rai Risk Unmutated B-CLL.. <i>Blood</i> , 2006 , 108, 2779-2779	2.2	
44	Chronic lymphocytic leukemia: current and emerging treatment approaches. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 1-10; quiz 11-2	0.6	8
43	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. <i>Blood</i> , 2005 , 105, 2099-106	2.2	38
42	A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. <i>Leukemia Research</i> , 2005 , 29, 1009-18	2.7	11
41	Diagnostic criteria for monoclonal B-cell lymphocytosis. <i>British Journal of Haematology</i> , 2005 , 130, 325-325	4.5	305
40	MBL and MoBL [Response to Ziegler-Heitbrock. <i>British Journal of Haematology</i> , 2005 , 130, 795-796	4.5	3
39	Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.. <i>Blood</i> , 2005 , 106, 2098-2098	2.2	3
38	Hypoxia Inducible Factor-1 β s over Expressed in CLL B Cells Because of an Impaired Proteasome Pathway Associated with Defective Interaction with von Hippel-Landau Protein.. <i>Blood</i> , 2005 , 106, 2115-2115	2.2	1
37	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005 , 106, 707-707	2.2	7
36	Tumor Cells Resistant to Alemtuzumab Complement Mediated Cytotoxicity in Patients with High Risk Previously Untreated Early Stage CLL: A Possible Mechanism of Treatment Failure.. <i>Blood</i> , 2005 , 106, 2973-2973	2.2	1
35	Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005 , 106, 3255-3255	2.2	
34	Molecular and Clinical Analysis of a Midwest Cohort of B-CLL Patients Utilizing the Immunoglobulin VH 1-69 Gene.. <i>Blood</i> , 2005 , 106, 5016-5016	2.2	

33	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 5420-5420	2.2	
32	Targeting V α -4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti V α -4 Therapy.. <i>Blood</i> , 2005 , 106, 1182-1182	2.2	
31	Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005 , 106, 3278-3278	2.2	
30	Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. <i>Leukemia and Lymphoma</i> , 2004 , 45, 79-84 ⁹	3 ⁰	
29	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. <i>Blood</i> , 2004 , 103, 1202-10	2.2	195
28	ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2004 , 351, 893-901	59.2	754
27	VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2004 , 104, 788-94	2.2	177
26	ZAP-70 Expression Associated with Activation in Normal Human B Cells and B Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004 , 104, 2794-2794	2.2	3
25	Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004 , 104, 339-339	2.2	16
24	Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway.. <i>Blood</i> , 2004 , 104, 1909-1909	2.2	
23	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. <i>Blood</i> , 2004 , 104, 1475-1475	2.2	
22	CLL B Cell Interaction with Bone Biopsy Generated Marrow Stromal Elements Enhances Their Apoptosis Resistance in Association with an Angiogenic Switch.. <i>Blood</i> , 2004 , 104, 1914-1914	2.2	
21	Elevated BlyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BlyS Polymorphisms.. <i>Blood</i> , 2004 , 104, 964-964	2.2	
20	Leukemic B Cells from CD38 Positive but Not CD38 Negative B-CLL Patients Express Heightened Levels of Cell Cycle Related Genes.. <i>Blood</i> , 2004 , 104, 4809-4809	2.2	1
19	Pathogenesis of Impaired Cellular Immune Function in CLL 2004 , 109-121		4
18	Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 121, 287-95	4.5	176
17	IL-4 biology: impact on normal and leukemic CLL B cells. <i>Leukemia and Lymphoma</i> , 2003 , 44, 897-903	1.9	36
16	Identification of a global gene expression signature of B-chronic lymphocytic leukemia. <i>Molecular Cancer Research</i> , 2003 , 1, 346-61	6.6	100

15	Chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2002 , 2002, 193-213	3.1	54
14	Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. <i>Blood</i> , 2001 , 98, 23-8	2.2	78
13	Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. <i>British Journal of Haematology</i> , 2001 , 112, 760-7	4.5	45
12	Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001 , 115, 854-61	4.5	163
11	Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression. <i>Journal of Clinical Immunology</i> , 1999 , 19, 239-46	5.7	5
10	The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. <i>Cancer</i> , 1999 , 86, 957-968	6.4	46
9	T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. <i>British Journal of Haematology</i> , 1998 , 100, 459-63	4.5	22
8	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997 , 90, 340-345	2.2	55
7	Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. <i>British Journal of Haematology</i> , 1997 , 96, 733-5	4.5	44
6	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997 , 90, 340-345	2.2	4
5	Tumor suppressor genes and clonal evolution in B-CLL. <i>Leukemia and Lymphoma</i> , 1995 , 18, 41-9	1.9	14
4	Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. <i>Leukemia and Lymphoma</i> , 1995 , 16, 351-4	1.9	9
3	Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. <i>American Journal of Hematology</i> , 1988 , 29, 152-63	7.1	346
2	Differential effect of hemodialysis membranes on human lymphocyte natural killer function. <i>Artificial Organs</i> , 1987 , 11, 165-7	2.6	13
1	T-cell subpopulations in multiple myeloma: correlation with clinical disease status. <i>British Journal of Haematology</i> , 1981 , 49, 629-34	4.5	38